(MENAFN- PR Newswire) Domuschiev Impact will lead philanthropic and sustainability efforts, including $5 million to develop a new Global Anti-Malaria Center.
NEW YORK AND SOFIA, Bulgaria, Sept. 19, 2023 /PRNewswire/ -- Kiril Domuschiev, President and CEO of Huvepharma, announced a $5 million plan to ensure low-cost and broad access to life-saving anti-malarial medications in the most endemic countries.
Domuschiev Impact, unveiled at the Clinton Global Initiative (CGI) conference in New York, plans to develop a new Global Anti-Malaria Center focused on bringing a truly competitive, no-profit-no-loss treatment for malaria to market. Domuschiev Impact will build upon groundbreaking research funded by the Bill & Melinda Gates Foundation. Continue Reading
Domuschiev Impact is committed to bold action and inspiring others as the world contends with unprecedented challenges.
"The general objective of this new center is to inspire innovation, rally funder support, and motivate researchers," explained Kiril.
"Marketplace instability and lack of access could endanger millions more lives. Huvepharma has spent significant resources – including research and capital investments – to develop low-cost treatments. This new center enablesto approach a more thorough economic evaluation to research and development," further detailed Nicola De Risi, CEO of Huvepharma Italia, who joined Mr. Domuschiev at CGI.
In addition to the commitments announced Tuesday, Domuschiev Impact is working with the Clinton Global Initiative and other partners to invest in training small, co-op farmers in Africa to expand healthy, sustainable animal protein production.
Over five years, Domuschiev Impact will provide small, co-op farmers with experts in livestock management, nutrition, veterinary services, and critical animal health products through the family's pharmaceutical company, Huvepharma. Combined, these goods and services will help ensure farmers are set up for long-term success, creating a more food-secure environment and a new generation of prosperity in some of the world's most challenging places.
"We are committed to the health and vitality of the global community, especially in parts of the world that are still developing," Kiril continued.
Echoing previstatements at CGI's first-ever meeting in Bulgaria earlier this year, Kiril also encouraged attendees and their organizations to take on ambitiprojects to tackle the world's toughest problems. "We believe that health, access, and sustainability result from businesses focused on making the communities we serve stronger, healthier, and more secure."
About Domuschiev Impact
Domuschiev Impact invests in science, innovation, and people. Leading philanthropic and sustainability efforts within the family's many companies, Domuschiev Impact is designed to impact global change by bringing partners across sectors to realize a more sustainable world.
Huvepharma is a fast-growing global Pharma company (in terms of sales growth) focusing on developing, manufacturing, and marketing animal and human health and nutraceutical products.
Huvepharma's key strengths lie in large-scale fermentation and technical expertise developed over more than half a century at our European manufacturing sites.
Huvepharma's products are sold in over 100 countries. The company operates production sites in France, a chemical synthesis plant in Italy, three production facilities for biotechnology and vaccines in Bulgaria, and six sites in the U.S. for vaccines and veterinary medicines.
International media contact:
+1 346 221-2636
Huvepharma Dutch media contact:
M +31 6 54 798 253
E [email protected]
Huvepharma International Sales Director Affiliates
+32 473 900 426
SOURCE Domuschiev Impact